Eliem Therapeutics Inc (ELYM)
8.17
-0.01
(-0.12%)
USD |
NASDAQ |
May 17, 16:00
8.17
0.00 (0.00%)
After-Hours: 20:00
Eliem Therapeutics Cash and Short Term Investments (Quarterly): 105.03M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 105.03M |
| December 31, 2023 | 106.80M |
| September 30, 2023 | 107.43M |
| June 30, 2023 | 102.63M |
| March 31, 2023 | 109.37M |
| December 31, 2022 | 123.57M |
| September 30, 2022 | 122.62M |
| Date | Value |
|---|---|
| June 30, 2022 | 122.95M |
| March 31, 2022 | 123.94M |
| December 31, 2021 | 136.48M |
| September 30, 2021 | 146.02M |
| June 30, 2021 | 99.48M |
| March 31, 2021 | 47.91M |
| December 31, 2020 | 20.49M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
20.49M
Minimum
Dec 2020
146.02M
Maximum
Sep 2021
105.34M
Average
108.40M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | 305.66M |
| Candel Therapeutics Inc | 25.71M |
| Cyclacel Pharmaceuticals Inc | 3.378M |
| Lipocine Inc | 24.63M |
| GlycoMimetics Inc | 31.28M |